Available Trials

Main Content

Phase I Studies

For more information regarding these studies, contact Cancer Research at (601) 984-1095.

Advanced malignancies

INCAGN 2390-101: A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN02390 in Participants with Select Advanced Malignancies

This study does not constitute treatment or therapy. INCAGN02390 is an investigational drug that is being studied by the Sponsor for use in the treatment of cancer. “Investigational” means that INCAGN02390 has not been approved by the US Food and Drug Administration (FDA) for use as a prescription or over-the-counter medication.

INCAGN02390 is a fully human, monoclonal antibody that binds to human TIM-3 protein on the surface of some immune cells. When TIM-3 is expressed on your immune cells, they may become less effective in killing tumor cells.  INCAGN02390 binds TIM-3 and may help immune cells maintain their effectiveness in killing tumor cells.

Principal Investigator: Shou-Ching Tang, MD